INOInovio Pharmaceuticals Inc
Compact View
Earnings Recap
• Reported GAAP EPS of -$0.28 up 45.10% YoY • INOVIO anticipates its cash, cash equivalents, and short-term investments will fund operations into Q1 2027, past the INO-3107 PDUFA date, including $16M from an April 2026 offering and an estimated $18M Q2 2026 cash burn.
Bullish
INOVIO's BLA for INO-3107 is actively reviewed by the FDA with a PDUFA date of October 30, 2026, and the company is advancing commercial readiness. INOVIO expanded its pipeline through a collaboration with Akeso Inc. and reduced R&D and G&A expenses.
Bearish
INOVIO faces declining cash reserves and regulatory uncertainty for its lead candidate INO-3107, with the FDA scheduling a meeting to discuss accelerated approval eligibility. The company also reported no revenue from collaborative arrangements in Q1 2026.